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http://dx.doi.org/10.1016/j.ccr.2012.08.024SUMMARYGlioblastoma (GBM) is a brain tumor that carries a dismal prognosis and displays considerable heteroge-
neity. We have recently identified recurrent H3F3A mutations affecting two critical amino acids (K27 and
G34) of histone H3.3 in one-third of pediatric GBM. Here, we show that each H3F3A mutation defines an
epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive
with IDH1 mutations, which characterize a third mutation-defined subgroup. Three further epigenetic
subgroups were enriched for hallmark genetic events of adult GBM and/or established transcriptomic signa-
tures. We also demonstrate that the two H3F3Amutations give rise to GBMs in separate anatomic compart-
ments, with differential regulation of transcription factors OLIG1, OLIG2, and FOXG1, possibly reflecting
different cellular origins.INTRODUCTION
Glioblastoma (GBM;World Health Organization [WHO] grade IV),
the most common primary brain tumor, carries a universally
dismal prognosis in children and adults (Louis et al., 2007).
With evidence emerging recently of age-specific molecular and
genetic differences, it is now becoming apparent that pediatric
GBM is largely biologically distinct from adult GBM. Based on
similarities in recurrent genomic aberrations (Bax et al., 2010;
McLendon et al., 2008; Paugh et al., 2010; Qu et al., 2010; Schiff-
man et al., 2010; Zarghooni et al., 2010), it was long thought
that pediatric GBMs more closely resembled adult ‘‘secondary’’
GBM, which arise from a preceding lower-grade lesion. How-
ever, stepwise transformation from less-malignant gliomas into
GBM rarely occurs in children (Broniscer et al., 2007). Further-
more, IDH1 or IDH2 mutations, which are found in up to 98%
of adult secondary GBM, are very rare in childhood GBM
(<10%) (Antonelli et al., 2010; Balss et al., 2008; De Carli et al.,
2009; Paugh et al., 2010; Pollack et al., 2011; Schiffman et al.,
2010; Setty et al., 2010; Yan et al., 2009).
We recently identified two recurrent somatic mutations in the
H3F3A gene, affecting highly conserved residues of its encoded
protein, the replication-independent histone 3 variant H3.3, in
one-third of pediatric GBMs (Schwartzentruber et al., 2012).
Mutations in a protein complex comprised of H3.3 and ATRX/Significance
GBM is the most common and also the most devastating brai
strong evidence that GBM can be subclassified into multiple
correlating with molecular-genetic factors as well as key clinica
tified six epigenetic GBM subgroups displaying characteristic
mutations, DNA copy-number alterations, and transcriptomic p
vative subgroup-specific treatments, e.g., targeted epigenetic
of future clinical trials. Our study enables classification of GBM
subgroups carrying clinical implications.
426 Cancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc.DAXX were detected in 45% of cases, and were shown to be
associated with TP53 mutations and alternative lengthening of
telomeres (ALT). The H3.3 mutations result in amino acid sub-
stitutions at K27 or G34—at or near residues targeted by key
post-translational modifications that regulate H3.3’s activity in
governing gene expression (Hyland et al., 2011)—and were
shown to be linked to distinct transcriptional profiles (Schwart-
zentruber et al., 2012).Methylation of K27 and K36 is also disrup-
ted by elevated levels of the onco-metabolite 2-hydroxyglutarate
(2-HG) resulting from gain-of-function mutations in IDH1
(Chowdhury et al., 2011; Xu et al., 2011), which was previously
shown to be associated with a distinct Glioma-CpG-Island
Methylator Phenotype (G-CIMP) (Noushmehr et al., 2010).
In the present study, we further investigate the heterogeneity
of glioblastoma across the entire age spectrum, and elucidate
the impact of H3F3A mutations on the GBM epigenome.
RESULTS
Integrated Molecular Classification of Glioblastoma
We used an integrative approach based on epigenetic, copy-
number, expression, and genetic analyses to investigate the
heterogeneity of glioblastoma across all age groups. An over-
view of all GBM samples subjected to various analyses is given
in Figure S1A available online.n tumor, with a 5-year survival rate below 10%. We present
groups, indistinguishable by histological appearance, but
l variables such as patient age and tumor location. We iden-
global DNA methylation patterns, harboring distinct hotspot
atterns. These findings may guide the identification of inno-
therapies for H3.3-mutated variants, and improve the design
across the entire age continuum into biologically meaningful
GBM samples (n = 210)
●● ●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●●
●
●
●
●●●●
●●●
●
●
●
●
●
●●
●●●
●
●●●
●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●●●
●●●
●●
●
●●●
●
●●●
●
●
●
●
●
●
●●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●●●●●
●
●
●
●●
●
●●●
●
● ●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
0
21
Age
60
90
PDGFRA ampl.
EGFR ampl.
CDKN2A del.
Chr. 10 loss
Chr. 7 gain
TP53
H3F3A
IDH1
TCGA Expression
TCGA Methylation
Methylation cluster
C
ol
or
 s
ca
le
(b
et
a-
va
lu
es
)
0
0.5
1
G34R/V
MUT
WT
NA
K27M
Controls
M
ut
at
io
ns
C
yt
og
en
et
ic
s
IDH K27 G34 RTK I 'PDGFRA' Mesenchymal RTK II 'Classic'
D
N
A
 m
et
hy
la
tio
n 
pr
ob
es
 (n
 =
 8
,0
00
)
G-CIMP+
Cluster #2
Cluster #3
Proneural
Neural
Classical
Mesenchymal
TCGA subgroups
M
et
hy
la
tio
n
E
xp
re
ss
io
n
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
Fe
ta
l n
or
m
al
 b
ra
in
 (n
=4
)
A
du
lt 
no
rm
al
 b
ra
in
 (n
=2
)
W
G
A
-D
N
A 
(n
=2
)
M
.S
ss
I-D
N
A 
(n
=2
)
U
nm
et
hy
la
te
d
M
et
hy
la
te
d
Figure 1. Methylation Profiling Reveals the Existence of Six Epigenetic GBM Subgroups
Heatmap of methylation levels in six GBM subgroups identified by unsupervised k-means consensus clustering, and control samples as indicated. Each row
represents a probe; each column represents a sample. The level of DNA methylation (beta-value) is represented with a color scale as depicted. For each sample
(n = 210), patient age, subgroup association, mutational status, and cytogenetic aberrations are indicated.
See also Figure S1 and Tables S1 and S2.
Cancer Cell
Epigenetic and Biological Subgroups of GlioblastomaWe investigated a cohort of GBMs from children (n = 59) and
adult patients (n = 77) for genome-wide DNA methylation
patterns using the Illumina 450k methylation array, and comple-
mented our data with unpublished profiles of 74 adult GBM
samples generated by The Cancer Genome Atlas (TCGA)
Consortium (McLendon et al., 2008) (Table S1). Consensus
clustering using the 8,000 most variant probes across the data
set robustly identified six distinct DNA methylation clusters
(Figures 1 and S1B). Based on correlations with mutational
status, DNA copy-number aberrations, and gene expression
signatures, as outlined below, we have labeled these subgroups
‘‘IDH,’’ ‘‘K27,’’ ‘‘G34,’’ ‘‘RTK I (PDGFRA),’’ ‘‘Mesenchymal,’’ and
‘‘RTK II (Classic).’’
A striking finding of this integrated analysis is that H3F3A K27
and G34 mutations were exclusively distributed to the K27
(18/18) andG34 (18/18) clusters, respectively (p < 0.001; Fisher’s
exact test) (Figure 1). The IDH group contained 88% of IDH1-
mutated tumors (23/26) (p < 0.001) and displayed concerted,Cglobal hypermethylation (Figures 1, 2A, and 2B), thereby ex-
panding the previously described link between IDH1 mutation
and G-CIMP+ tumors to a pediatric setting (Noushmehr et al.,
2010). In contrast, tumors in the G34 cluster specifically showed
widespread hypomethylation across the whole genome, and
especially in nonpromoter regions, when compared with all other
subgroups (Figures 2A and 2B). This suggests the existence of
a more global version of a CpG hypomethylator phenotype
(CHOP), as proposed for a small number of genes in gastric
cancer (Kaneda et al., 2002). More detailed mapping of differen-
tially methylated regions revealed that the hypomethylation
observed in H3F3A G34-mutated tumors was particularly prom-
inent at chromosome ends (Figures 2C and 2D), potentially link-
ing subtelomeric demethylation to alternative lengthening of
telomeres, which is most frequently observed in this subgroup
(Schwartzentruber et al., 2012).
Of note, all mutations inH3F3A and IDH1were mutually exclu-
sive (p < 0.001) (Figure 1). To further test this observation, weancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc. 427
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Figure 2. Global DNA Methylation Patterns in GBM Subgroups
(A) Distinct patterns of global DNA methylation in GBM subgroups as identified by consensus clustering. The empirical cumulative distribution function for DNA
methylation levels (beta-values) is plotted individually for each subgroup.
(B) Overall DNAmethylation levels (mean beta-values) of individual GBMmethylation subgroups. Significant differences (***p < 0.001; **p < 0.01; *p < 0.05) to IDH
and G34 subgroups are indicated.
(C) Upper panel: Probe density in respect of distance to chromosome end. The fraction of probes located within CpG-Islands (red line) remains stable. Lower
panel: Mean methylation value per subgroup within windows of 500kb, normalized to control samples. Individual samples are normalized by the mean overall
methylation value.
(D) Mean methylation value within 4 Mb to the chromosome end normalized to the mean overall methylation value and to control samples. Significant differences
(***p < 0.001) between subgroups compared to G34 tumors are indicated. MES, Mesenchymal.
See also Figure S2.
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Cancer Cell
Epigenetic and Biological Subgroups of Glioblastomaextended the targeted sequencing analysis of H3F3A and IDH1
to include 460 GBM samples from patients covering a broad
age range (Figure S1C; Table S2). Even in this expanded series,
no co-occurring mutations in H3F3A and IDH1 were detected
(p < 0.001), and the age distribution confirmed reported associ-
ations of certain mutations with GBM in children (H3F3A K27),
adolescent patients (H3F3A G34), and young adult patients
(IDH1) (Khuong-Quang et al., 2012; Schwartzentruber et al.,
2012; Yan et al., 2009) (Figure S1C; Table S2). As we have
shown, TP53 mutations largely overlap with H3F3A mutations
in pediatric GBM (Schwartzentruber et al., 2012), similar to the
association of TP53 and IDH1 mutations in adults (Yan et al.,
2009). This observation also holds true in our larger cohort,
with a high enrichment of TP53 mutations in the G34 (18/18),
IDH (22/24), and K27 (13/18) clusters (p < 0.001) (Figure 1).
Since pediatric GBMs have been shown to display a distinct
spectrum of focal copy-number aberrations (CNAs) compared
with their adult counterparts (Bax et al., 2010; Paugh et al.,
2010; Qu et al., 2010), we integrated DNA methylation clusters
with copy-number data derived from the methylation arrays
(Figures 1 and S1D). Interestingly, PDGFRA amplification was
significantly more common in the RTK I ‘‘PDGFRA’’ cluster
than any other subgroup (11/33; p < 0.001), hence our pro-
posed name for this group. The RTK II ‘‘Classic’’ cluster demon-
strated a very high frequency of whole chromosome 7 gain
(50/56; p < 0.001) and whole chromosome 10 loss (56/56;
p < 0.001), as well as frequent homozygous deletion of CDKN2A
(35/56; p < 0.001) and amplification of EGFR (39/56; p < 0.001)
(Figures 1 and S1D)—all hallmark CNAs of adult GBM
(Louis et al., 2007), as reflected by the complete absence of pedi-
atric patients in this cluster. Overall, tumors from the IDH, K27,
and G34 clusters were mostly devoid of the detected CNAs
associated with the other GBM subgroups (amplifications of
PDGFRA and EGFR, deletion of CDKN2A, chromosome 7 gain,
and chromosome 10 loss) (Figure 1; Table S1), in keeping
with a previously reported finding in G-CIMP+ tumors (Noush-
mehr et al., 2010).
To additionally place the methylation subgroups proposed
here into the context of previous GBM classification systems,
we used the gene expression signature described by the
TCGA to classify 122 of the above tumors with available tran-
scriptome data into one of four gene expression subtypes:
Proneural, Neural, Mesenchymal, and Classical (Verhaak et al.,
2010) (Figure 1; Table S1). This further confirmed the prototypic
nature of tumors in the RTK II ‘‘Classic’’ cluster, which was
clearly enriched for ‘‘Classical’’ expression profiles (p < 0.001).
The RTK I ‘‘PDGFRA’’ cluster was highly enriched for ‘‘Proneu-
ral’’ expression (p = 0.01), further substantiating the previously
reported association of PDGFRA amplification with this expres-
sion subtype (Verhaak et al., 2010). As expected, all tumors in
the IDH cluster displayed ‘‘Proneural’’ expression patterns. Inter-
estingly, the K27 cluster also showed a clear enrichment of
tumors with a ‘‘Proneural’’ signature (p < 0.01), indicating that
this expression subtype can be divided into subgroups harboring
distinct genomic aberrations based on methylation profiling and
targeted gene sequencing. ‘‘Mesenchymal’’ gene expression
was mostly restricted to one methylation subgroup (p < 0.001),
that showed a much lower incidence of typical GBM-related
CNAs, generally fewer copy-number changes, and no character-Cistic point mutations. We therefore termed this methylation
cluster, which displayed the largest similarity with normal brain
methylation patterns, ‘‘Mesenchymal.’’ Copy-number aberra-
tions in these samples were, however, observed at a similar
amplitude as in other cases, indicating an absence of excess
stromal contamination.
Our finding of six GBM methylation clusters is different from
a TCGA study using Illumina 27k arrays, which identified three
methylation clusters in an adult GBM cohort (Noushmehr et al.,
2010). Applying their signature to our data set, however, showed
that two clusters (G-CIMP+ and Cluster #3) mapped almost
exactly to two of our subgroups (IDH and RTK II ‘‘Classic,’’,
respectively, p < 0.001) (Figure 1). By adding pediatric cases to
the study cohort, we demonstrate that TCGAmethylation Cluster
#2 can be further divided into four biologically distinct sub-
groups, defined by a clear enrichment for mutations (K27,
G34), CNAs (PDGFRA), and/or gene expression signatures
(Mesenchymal). The same DNA methylation clusters were
apparent when restricting our analyses to the pediatric popula-
tion, with the exception of the RTK II ‘‘Classic’’ cluster, which
is not represented in the pediatric population (Figure S1E).
Notably, by analyzing tumors from patients spanning a broad
age spectrum, we further observed a clear age-dependent
increase in overall DNA methylation levels (Figure S2A), even
after adjusting our analysis to exclude tumors with age-related
mutations in IDH1 or H3F3A (Figure S2B).
GBM Subgroups Show Correlations with
Clinicopathological Variables
The DNA methylation clusters described here were closely
associated with specific age groups, pointing toward the biolog-
ical diversity of epigenetic GBM subgroups (Figure 1). While the
K27 cluster predominantly consisted of childhood patients
(median age 10.5 years, range 5–23 years), patients in the G34
cluster were found mostly around the threshold between the
adolescent and adult populations (median age 18 years, range
9–42 years), as previously suggested (Schwartzentruber et al.,
2012). The RTK I ‘‘PDGFRA’’ cluster also harbored a proportion
of pediatric patients (median age 36 years, range 8–74 years), in
line with reports of PDGFRA CNAs being more prevalent in
childhood high-grade gliomas (Bax et al., 2010; Paugh et al.,
2010; Qu et al., 2010). The Mesenchymal cluster displayed a
widespread age distribution (median age 47, range 2–85 years).
The IDH and RTK II ‘‘Classic’’ clusters were mostly comprised of
younger adult (median age 40 years, range 13–71 years) and
older adult (median age 58, range 36–81 years) patients, respec-
tively, reflecting the established differences in patient age
between IDH1-mutated/G-CIMP+ and IDH1 WT adult GBM
(Noushmehr et al., 2010; Yan et al., 2009).
The epigenetic GBM subgroups identified here also showed
mutation-specific patterns of tumor location in the central
nervous system (Figure 3A). While K27-mutated tumors were
predominantly seen in midline locations, e.g., thalamus, pons,
and the spinal cord (21/25 cases with available data), tumors
from all other subgroups almost exclusively arose in the cerebral
hemispheres (86/92, p < 0.001). To further investigate this asso-
ciation of mutation type and location, we investigated the tran-
scriptomic profiles of H3F3A-mutated samples (n = 13). Gene
signatures characteristic for K27 and G34 mutant GBMs wereancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc. 429
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Figure 3. Epigenetic Subgroups of GBM Correlate with Distinct Clinical Characteristics
(A) Location of 119GBMs in the human central nervous systemgrouped bymethylation clusters. The number of cases in each group is indicatedwithin the circles.
Circles without numbers represent single cases. Different colors indicate methylation cluster affiliation. Tumors occurring in midline locations are depicted in the
sagittal view (left panel), tumors occurring in the cerebral and cerebellar hemispheres are depicted in the exterior view (right panel).
(B and C) Kaplan-Meier survival curves for GBM subgroups defined by methylation profiling (B), and mutation analysis (C). The p values were computed by log
rank tests between subgroups.
See also Figure S3.
Cancer Cell
Epigenetic and Biological Subgroups of Glioblastomaapplied to a published series of 1,340 transcriptomic profiles
representing multiple regions of the developing and adult human
brain (Kang et al., 2011; Figure S3). The G34 mutant signature
appeared to be most strongly expressed in early embryonic
regions and early- to mid-fetal stages of neocortex and striatum
development. In contrast, the K27 signature most closely
matched with mid- to late-fetal stages of striatum and thalamus
development. Thus, G34 and K27 mutant GBMs seem to show
expression patterns of early developmental stages correlating
with their subsequent tumor location, possibly indicating
different cellular origins and/or time of tumor initiation for these
two subgroups.430 Cancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc.Correlating our proposed methylation clusters with patient
survival indicated differences between mutation-defined sub-
groups, but this was somewhat restricted by the low number
of patients with available survival data in each subgroup (Fig-
ure 3B). We therefore enlarged our survival analysis to include
all tumors with known H3F3A and IDH1 mutation status (Fig-
ure 3C). As expected, patients with IDH1 mutant tumors had a
significantly longer overall survival (OS) than patients with
H3F3A and IDH1 WT tumors (p < 0.001) (Noushmehr et al.,
2010; Parsons et al., 2008; Yan et al., 2009). Notably, G34mutant
GBM patients also showed a trend toward a better OS than WT
tumor patients, with marginal statistical significance (p = 0.05). In
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Figure 4. Identification of Marker Genes Affected by Differential Methylation and Expression in GBM Subgroups
(A andB) Volcanoplots illustratingdifferences inDNAmethylation (A) andgeneexpression (B) between tumors from theK27andG34subgroups.Difference inbeta-
values (A) and Log2 fold change in gene expression values (B) are plotted on the x axis, adjusted p values calculated using theSAMmethodare plotted on the y axis.
(C) Starburst plot integrating DNA methylation (x axis) and gene expression (y axis) data.
(D) Methylation levels at the OLIG1 and OLIG2 loci across all 210 GBM samples investigated. Each row represents one sample; each vertical bar represents one
CpG-site. Light blue bars indicate promoter regions. Methylation levels are represented by a color scale as indicated.
(E) Mean gene expression levels ofOLIG1 (upper panel) andOLIG2 (lower panel) across GBM subgroups (n = 48). Significant differences (***p < 0.001; **p < 0.01;
*p < 0.05) between subgroups compared to G34 tumors are indicated.
(F) Inverse correlation of promoter methylation (x axis) and gene expression (y axis) of OLIG2 across GBM methylation subgroups (n = 48; Pearson’s correlation
coefficient, r). MES, Mesenchymal.
See also Figure S4 and Table S3.
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Epigenetic and Biological Subgroups of Glioblastomacontrast, patients with K27 mutations tended toward an even
shorter OS than patients with WT tumors, although this did not
reach statistical significance (p = 0.12). Comparing the two
H3F3A mutations, patients harboring G34-mutated tumors
clearly had a longer OS than patients with tumors carrying the
K27 mutation (p < 0.01). While this association may be partly
linked to G34-mutated tumors being more accessible to surgery
than the midline K27-mutated tumors, the better prognosis of
G34 versus K27 was independent of location for those cases
where both mutation type and tumor site information were avail-
able (p = 0.02; HR = 0.20, 95% CI = 0.05–0.77; Cox proportional
hazards model).
Integrating Methylome and Transcriptome Data
Identifies Marker Genes of GBM Subgroups
A combined analysis of DNA methylation and gene expression
data was used to identify subgroup-specific differentially regu-Clated genes (Figures 4A–4C and S4A–4C; Table S3). This anal-
ysis revealed Oligodendrocyte Lineage Genes 1 and 2 (OLIG1
and OLIG2) and the neural development gene FOXG1 as top
candidates for further analysis in H3F3A-mutated GBMs (Fig-
ure 4A–4C). DNA hypermethylation across the OLIG1 and
OLIG2 loci occurred exclusively in G34-mutated tumors, which
concurrently displayed significantly lower OLIG1 and OLIG2
gene expression (Figure 4D–4F). Interestingly, this pattern
closely mimics that of embryonic stem cells, where epigenetic
inactivation of OLIG1 and OLIG2 has been proposed as a mech-
anism to prevent neural lineage commitment (Meissner et al.,
2008). Expression of FOXG1 was significantly lower in K27-
mutated tumors than in all other subgroups, accompanied by
higher levels of promoter methylation (Figures S4A, S4D, and
S4E). This comparative analysis also further supported our
suggestion of a CHOP-like phenotype in G34 tumors, as most
of the differentially methylated genes were found to beancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc. 431
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Figure 5. Identification of H3F3A-Mutated GBMs by Differential Protein Expression Patterns
(A) Classification of 143 pediatric GBMs according to protein expression of OLIG2, FOXG1, andmutated IDH1 (IDH1R132H). Numbers in brackets indicate samples
with known H3F3A and IDH1 mutation status as predicted by immunohistochemistry and verified by targeted gene sequencing, respectively.
(B) Typical pattern of OLIG2/FOXG1+ cells with concomitant loss of ATRX protein expression and ALT as observed in G34-mutated GBMs. Insets show
contrasting staining results for comparison. Scale bars represent 100 mm unless indicated differently.
(C and D) Correlation of GBMs as classified in (A) with ATRX loss (C), and ALT (D).
See also Figure S5 and Table S4.
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Epigenetic and Biological Subgroups of Glioblastomahypomethylated (1653/1946, 85%, Figure S4B) in this subgroup,
in contrast to the hypermethylator G-CIMP pattern observed in
the IDH subgroup (Figure S4C). Hypermethylation and concur-
rent downregulation of TP73 antisense RNA 1 (TP73-AS1) was
identified as a unique characteristic of this IDH/G-CIMP+ cluster
(Figures S4D and S4F). Interestingly, inactivation of this gene by
promoter methylation has been reported as a common mecha-
nism in a high proportion of oligodendrogliomas, 80% of which
are also known to harbor IDH1 mutations (Pang et al., 2010).
Immunohistochemical Analysis Correctly Subclassifies
Mutation-Defined GBM Subgroups
In an attempt to subgroup GBM samples based on differential
protein expression—amethod which is likely to be more suitable
for possible clinical application—we used commercially avail-
able antibodies against OLIG2, FOXG1, and mutated IDH1
(R132H) to stain a tissue-microarray (TMA) with cores from 143
pediatric GBMs, and classified tumors according to their protein
expression patterns (Figures 5A and 5B; Table S4). The resulting
fractions of tumors with predicted mutations in IDH1 (IDH1R132H,
n = 6) andH3F3A (OLIG2+/FOXG1 for K27, n = 37, and OLIG2/
FOXG1+ for G34, n = 21) were consistent with the frequency of
each mutation in the pediatric population as detected by tar-
geted gene sequencing (Figure S1C). Our approach correctly
classified GBMs with known H3F3A and IDH1 mutation status,
and revealed a frequent association between OLIG2/FOXG1+
tumors (assumed to be G34-mutated), loss of ATRX protein
expression, and an ALT phenotype (Figures 5B–D), as previously
reported for H3F3A G34-mutated tumors (Schwartzentruber
et al., 2012). The putative H3F3A mutant groups also did not
overlap with tumors harboring IDH1 (R132H) mutations, and
only one case with EGFR amplification and homozygous432 Cancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc.CDKN2A deletion was detected therein (Figure S5A). The corre-
lation with clinicopathological variables, such as tumor location
and patient survival, also reflected our findings from the array-
based analysis (Figures S5B and S5C). Of note, rare tumors
represented on the TMA occurring in the basal ganglia and the
spinal cord were almost always found in the OLIG2+/FOXG1
subgroup (and therefore predicted to harbor the H3F3A K27
mutation), further strengthening our hypothesis of the H3F3A
K27 mutation as a unifying characteristic of midline GBM.
DISCUSSION
We have identified six biological subgroups of GBM based on
global DNA methylation patterns, which correlate with specific
molecular-genetic alterations and key clinical parameters. Our
findings suggest that at least 30%–40% of pediatric/young adult
GBMs are likely characterized by disrupted epigenetic regula-
tory mechanisms, associated with recurrent and mutually exclu-
sive mutations in either H3F3A or IDH1, and aberrant DNA
methylation patterns. Placing these subgroups into the context
of previous molecular GBM classification schemes described
by the TCGA (Noushmehr et al., 2010; Verhaak et al., 2010)
revealed a clear correlation with DNA methylation clusters and
a corresponding enrichment for previously established expres-
sion signatures in different epigenetic subgroups. We have
also demonstrated that our proposed classification can refine
that described by the TCGA for adult GBM, to give a stratification
system that is applicable across all ages, and defines additional
biologically meaningful subgroups. A simplified graphical sum-
mary of the key molecular and biological characteristics of the
GBM subgroups as identified by our integrated classification
strategy is given in Figure 6.
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Figure 6. Graphical Summary of Key Molecular and Biological Characteristics of GBM Subgroups
Simplified schematic representation of key genetic and epigenetic findings in six GBM subgroups as identified by methylation profiling and correlations with
clinical patient data.
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Epigenetic and Biological Subgroups of GlioblastomaWe and others have recently described a high frequency of
H3F3A K27 mutations in thalamic GBMs and in diffuse intrinsic
pontine gliomas (DIPGs), suggesting that the latter likely repre-
sent an anatomically-defined subset of K27 mutant GBM
(Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Wu
et al., 2012). We now extend this observation to a larger
subgroup of GBM, characterized by the K27M mutation, which
almost exclusively occurs in midline locations, including rare
tumors in the basal ganglia and the spinal cord. This is in line
with a recent study by Puget et al. (2012) in which gene expres-
sion patterns of brainstem gliomas were found to resemble
midline/thalamic tumors, indicating a closely related origin. The
K27 subgroup also displays markedly lower expression of the
ventral telencephalic marker FOXG1 than other subgroups.
Conversely, non-K27 tumors were restricted to hemisphericClocations, further underlining the biological divergence of epige-
netic GBM subgroups. While recurrent focal amplification of
PDGFRA has been suggested as a key oncogenic event in pedi-
atric DIPGs in some studies (Paugh et al., 2011; Puget et al.,
2012; Zarghooni et al., 2010), midline-associated tumors in the
K27 or OLIG2+/FOXG1 subgroups (including ten brainstem
gliomas with known PDGFRA copy-number status) lacked this
common feature in our series. PDGFRA amplification was,
however, enriched in a subgroup of supratentorial hemispheric
GBMs. In part, this discrepancy may be explained by the use
of autopsy (and therefore post radio/chemotherapy) material
in previous study cohorts of DIPGs, which might have been
confounded by the higher incidence of PDGFRA amplifications
observed in radiation-induced gliomas (Paugh et al., 2010).
Nevertheless, amplifications of PDGFRA have also beenancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc. 433
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Epigenetic and Biological Subgroups of Glioblastomadetected in small numbers of pretreatment samples (Paugh
et al., 2011; Puget et al., 2012; Zarghooni et al., 2010), and
post-treatment samples were not found to show increased
widespread genomic instability (Paugh et al., 2011). This partic-
ularly clinically challenging subset of tumors clearly warrants
further investigation, underlining the importance of routine
stereotactic biopsy of DIPGs at the time of primary diagnosis.
OLIG2 has previously been reported as a universal marker
for diffuse gliomas (Ligon et al., 2004), and OLIG2-positive
progenitor-like cells of the subventricular zone have been sug-
gested as potential glioma-initiating cells (Wang et al., 2009).
There is also evidence that OLIG2-mediated modification of
p53 function is required for complete inactivation of the latter
in malignant gliomas, which typically show indirect loss of
p53 activity through MDM2 amplification or p14ARF deletion
(Mehta et al., 2011). Here, we describe a distinct subgroup of
GBM, harboring the H3F3A G34 mutation, in which OLIG1
and OLIG2 protein expression is absent. Given the 100%
mutation frequency of TP53 in this subgroup, this may indicate
a different pathogenesis of G34-mutated GBM, in which
direct inactivation of p53 is required rather than via an OLIG2-
dependent mechanism.
The previously reported association of H3F3A mutations,
particular the G34 mutation, with loss of ATRX and ALT
(Schwartzentruber et al., 2012) is further expanded upon here.
Interestingly, the global CHOP that we observed in G34 mutants
was particularly pronounced in subtelomeric regions, suggesting
a possible mechanistic link with ALT in these tumors (Gonzalo
et al., 2006). Whether this is a more general phenotype that
can be observed in clinically and etiologically distinct subgroups
of other human cancers, remains to be investigated.
The close link between H3F3A mutation type, tumor location,
and differential expression of key neuronal lineagemarkers leads
us to speculate that there may be differences in the cell of origin
and/or the time of tumor development between these GBM
subgroups. Although supported by the differential expression
of mutant-specific gene signatures at different stages of human
brain development, this remains to be formally shown. Also
requiring further validation in larger, prospective cohorts is the
association of the G34 mutation with better overall survival
compared with H3F3A and IDH1 WT tumors, and that of K27
mutation with potentially poorer prognosis, as observed in our
series and a recent cohort of pediatric DIPGs (Khuong-Quang
et al., 2012).
Given the location of the H3F3A mutations at or near critical
regulatory histone residues, and their distinct methylation pro-
files, we consider it likely that the H3.3 mutations are directly
involved in producing widespread aberrant DNA methylation
and deregulation of gene expression. This has recently been
shown for IDH1 mutations, which alone are sufficient to induce
the global epigenetic reprogramming of the G-CIMP phenotype
in normal astrocytes (Turcan et al., 2012). Overproduction of
the oncometabolite 2-hydroxyglutarate in IDH1-mutated cells
inhibits the TET family of 5-methlycytosine hydroxylases and
H3K27-specific demethylases. This is thought to lead to de-
creased 5-hydroxylmethycytosine and increased H3K27methyl-
ation (Xu et al., 2011), resulting in aberrant DNA and histone
methylation, and a block to differentiation (Christensen et al.,
2011; Dang et al., 2009; Lu et al., 2012).434 Cancer Cell 22, 425–437, October 16, 2012 ª2012 Elsevier Inc.Seminal studies have shown that DNA methylation patterns
are tightly linked to histone 3 lysine K27 trimethylation
(H3K27me3) patterns (Brinkman et al., 2012; Statham et al.,
2012), and in high-CpG-density promoters, loss of H3K4me3
and retention of H3K4me2 or H3K27me3 is correlated with an
increase in DNA methylation (Meissner et al., 2008). Therefore,
mutations affecting H3K27 methylation are likely to affect DNA
methylation. In addition, mutations in ATRX have been shown
to give rise to changes in the patterns of DNA methylation of
several highly repeated sequences, which further supports the
link between chromatin remodeling machinery and DNA methyl-
ation (Gibbons et al., 2000). Based on our current knowledge, the
incorporation of H3.3 variants into the genome, and the subse-
quent effects on gene regulation, involve the H3.3 chaperone
complex (including ATRX andDAXX) in a replication independent
manner (Drane´ et al., 2010; Goldberg et al., 2010) but other
factors also likely play a role. The exact mechanism by which
the H3F3A mutations might be inducing epigenetic reprogram-
ming requires further elucidation.
In conclusion, this study describes a number of findings that
enhance our understanding of the heterogeneity of GBM, as
well as shedding light on potential cellular origins and oncogenic
pathways leading to gliomagenesis. We have identified potential
prognostic biomarkers, which may be further exploited for
molecular diagnostic purposes, and also provided a focus for
future work at a basic and translational/targeted therapeutic
level, particularly in a pediatric and young adult setting.EXPERIMENTAL PROCEDURES
Patients and Tumor Samples
Primary tumor samples for methylation (n = 136; Table S1), mutation (n = 460;
Table S2), and gene expression (n = 69) analysis and all clinical data were
collected at the DKFZ (Heidelberg, Germany) and at McGill University (Mon-
treal, Canada). Paraffin-embedded samples (n = 143; Table S4) for TMA anal-
ysis were collected from the Burdenko Neurosurgical Institute (Moscow,
Russia) and from the Department of Neuropathology, University of Wu¨rzburg
(Germany). Patient clinical details can be found in Table S1 for the methylation
analysis data set and in Table S4 for the TMA cohort. All of the tumors were
banked at the time of primary diagnosis between 1994 and 2011 in accordance
with research ethics board approval from the respective institutes. Informed
consent was obtained from all patients included in this study. An overview of
all samples included in different data collections is given in Figure S1A. All of
the samples were independently reviewed by senior pediatric neuropatholo-
gists (S.A. and A.K.) according to the WHO guidelines. Detailed information
about samples provided by TCGA can be found elsewhere (http://
cancergenome.nih.gov).
DNA Methylation Profiling
For genome-wide assessment of DNAmethylationGBM samples (n = 136) and
controls (n = 10; four fetal and two adult samples of non-neoplastic cere-
bellum; two samples of Whole-Genome Amplified DNA (unmethylated control;
two samples of M.SssI-treated DNA [100% methylated control]) were arrayed
using the Illumina HumanMethylation450 BeadChip according to themanufac-
turer’s instructions at the DKFZ. Methylation data of additional adult glioblas-
toma samples (n = 74) were obtained from the TCGA website (https://
tcga-data.nci.nih.gov; available data from TCGA batches 79 and 111).
The following filtering criteria were applied: Removal of probes targeting the
X and Y chromosomes (n = 11,551), removal of probes containing a single-
nucleotide polymorphism (dbSNP132 Common) within five base pairs of and
including the targeted CpG-site (n = 24,536), and probes notmapping uniquely
to the human reference genome (hg19) allowing for one mismatch (n = 9,993).
In total, 438,370 probes were kept for analysis.
Cancer Cell
Epigenetic and Biological Subgroups of GlioblastomaFor a subset of differentially methylated genes from the 450k array,
MassARRAY technology (Sequenom, San Diego, CA, USA) was used to vali-
date our results, allowing us to compare DNA methylation levels at 29
individual CpG-sites investigated by both techniques. DNA methylation
measurements of those 29 CpG dinucleotides were highly correlated (median
Pearson’s correlation: r = 0.96; range: 0.71–1.00).
Gene Expression Profiling
Glioblastoma samples for which RNA of sufficient quantity and quality was
available (n = 69) were analyzed on the Affymetrix GeneChip Human Genome
U133 Plus 2.0 Array at the Microarray Department of the University of Amster-
dam, the Netherlands. Sample library preparation, hybridization, and quality
control were performed according to the manufacturer’s protocols. Expres-
sion data were normalized using the MAS5.0 algorithm of the GCOS program
(Affymetrix Inc). Gene expression data of additional adult glioblastoma
samples (n = 74) were obtained from the TCGA website (https://tcga-data.
nci.nih.gov; available data from TCGA batches 79 and 111). Predictive analysis
of microarrays was used to assign TCGA methylation and gene expression
subgroups to each of the samples in the present study.
Detection of CNAs
Copy-number aberrations were detected from the 450k Infinium methylation
array in a custom approach using the sum of both methylated and unmethy-
lated signals (Figure S1D). For the detection of EGFR and PDGFRA high-level
amplifications, homozygous CDKN2A deletions, and CNAs affecting chromo-
somes 7 and 10 (as depicted in Figure 1), automatic scoring was verified by
manual curation of the respective loci for each individual profile, and compared
with results obtained from SNP profiling and fluorescence in situ hybridization
(FISH) analysis where available. The three methodologies showed very high
concordance.
Statistical Analysis and Measurement of Differential DNA
Methylation and Gene Expression
For unsupervised consensus clustering we used the 8,000 most variable
methylatedprobes (by standarddeviation) across thedataset (Rpackage: clus-
terCons) (Monti et al., 2003;Wilkerson andHayes, 2010). The consensusmatrix
wascalculatedusing thek-meansalgorithm (10 randomstartingsets,maximum
of 1,000 iterations) on a fraction of probes (0.8) in 1,000 iterations. The signifi-
cance analysis of microarrays (SAM) method was used to identify genes that
are differentially methylated or differentially expressed between subgroups.
Correction for multiple testing was performed using the Benjamini-Hochberg
method. Genes were considered significantly differentially methylated/ex-
pressed between two subgroups when displaying an adjusted p value < 0.01
and a methylation difference of 0.2 or a 2-fold change in expression.
Statistical Analysis of Clinical and Molecular Data
Kaplan-Meier analysis was performed to estimate the survival time of different
GBM subgroups and a log rank test was used to test for differences of more
than one survival curve. Comparisons of binary and categorical patient char-
acteristics between subgroups were performed by the use of a two-sided
Fisher’s exact test. An unpaired t test was used to test for differences between
the mean values for continuous variables in GBM subgroups.
Immunohistochemistry and FISH
Hematoxylin and eosin stained sections from all 143 paraffin blocks were
prepared to define representative tumor regions for inclusion in the TMA. Anti-
bodies against the following antigens were applied: OLIG2 (Millipore, Billerica,
MA, USA; AB9610; dilution 1:250), FOXG1 (Abcam, Cambridge, UK; ab18259;
dilution 1:50), ATRX (Sigma, HPA001906; dilution 1:750), and mutated IDH1
(R132H; (Capper et al., 2010; dianova, DIA H09). Multicolor interphase FISH
analysis for PDGFRA, EGFR, and CDKN2A was performed as described
(Pfister et al., 2009). Telomere-specific FISH was done using a standard
formalin-fixed paraffin-embedded FISH protocol (Heaphy et al., 2011) using
a FITC peptide nucleic acid telomere probe from Dako (Glostrup, Denmark).
Genomic Sequencing
Targeted sequencing ofH3F3A (first coding exon), IDH1 (exon 4), and TP53 (all
exons) was performed by QIAGEN (Hilden, Germany) in both forward andCreverse directions using purified PCR products. PCR procedures were as
previously described (Pfaff et al., 2010). Primer sequences are available
upon request.ACCESSION NUMBERS
The complete CpG methylation values have been deposited in NCBI’s Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo) and are acces-
sible through GEO Series accession number GSE36278. The complete gene
expression values are accessible through GEO Series accession numbers
GSE36245 and, as part of a previously reported series, GSE34824 (Schwart-
zentruber et al., 2012).SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.08.024.
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